Core Insights - Jade Biosciences, Inc. reported a productive second quarter, closing a reverse merger and significant financing while advancing its pipeline for autoimmune disease therapies [2][5] - The company presented preclinical data for its lead candidate, JADE101, which shows potential as a best-in-class therapy for IgA nephropathy [5][6] - Jade is transitioning into a clinical-stage company, with plans for a Phase 1 study of JADE101 expected to begin in Q3 2025 [5][6] Financial Results - As of June 30, 2025, Jade had cash and cash equivalents of $220.9 million, which is expected to support operations through 2027 [10][13] - Research and Development (R&D) expenses for Q2 2025 totaled $22.5 million, while General and Administrative (G&A) expenses were $5.2 million [10][14] - The net loss for Q2 2025 was $32.1 million, including non-cash stock-based compensation of $4.0 million [10][15] Pipeline and Corporate Updates - JADE101 is an anti-APRIL monoclonal antibody targeting IgA nephropathy, with a Phase 1 study anticipated to start in Q3 2025 [3][5] - JADE201, another development candidate, is on track to enter clinical trials in the first half of 2026 [6][8] - Brad Dahms has been appointed as Chief Financial Officer, bringing extensive biopharmaceutical and investment banking experience [4]

SAN FRANCISCO and VANCOUVER, British Columbia, July 08, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in two upcoming investor conferences. Jade’s Chief Executive Officer, Tom Frohlich, and Chief Scientific Officer and Head of R&D, Andrew King, BVMS, Ph.D., will participate in a fireside chat at the H.C. Wainwright 4th Annual Kidney Virtual Conference o ...

Core Insights - Jade Biosciences, Inc. has appointed Brad Dahms as Chief Financial Officer, bringing extensive experience in guiding biotech companies through growth phases [1][2] - The company is focused on developing innovative therapies for autoimmune diseases, with its lead candidate, JADE101, targeting IgA nephropathy and expected to enter clinical trials in the second half of 2025 [3] Company Overview - Jade Biosciences specializes in creating best-in-class therapies for autoimmune diseases, with a pipeline that includes JADE101 and JADE201, as well as an undisclosed antibody discovery program, JADE-003 [3] - The company was established based on assets licensed from Paragon Therapeutics, an antibody discovery engine [3] Leadership Background - Brad Dahms has a strong track record in the biotech sector, having previously served as CFO and Chief Business Officer at IDRx, where he led the company through a significant sale to GSK for up to $1.15 billion [2] - His prior roles include CFO positions at Theseus Pharmaceuticals and Selecta Biosciences, where he was instrumental in securing financing and forming strategic partnerships [2]

Core Viewpoint - Jade Biosciences is advancing its investigational anti-APRIL monoclonal antibody, JADE101, for the treatment of IgA nephropathy, with new preclinical data to be presented at the 62nd European Renal Association Congress [1][2]. Company Overview - Jade Biosciences, Inc. is a biotechnology company focused on developing therapies for autoimmune diseases, with its lead candidate, JADE101, targeting the cytokine APRIL for IgA nephropathy [5]. - The company plans to initiate a first-in-human clinical trial for JADE101 in the second half of 2025 [5]. Product Details - JADE101 is designed to reduce pathogenic IgA levels, decrease proteinuria, and preserve kidney function in patients with IgA nephropathy [4]. - The antibody is engineered with half-life extension technology, allowing for dosing at intervals of at least eight weeks, enhancing patient convenience [4]. Upcoming Events - Jade Biosciences will host a conference call and webcast on June 9, 2025, to discuss the new data on JADE101 presented at the ERA Congress [2][3]. - The presentation titled "Discovery and Characterization of JADE101" will occur during the Focused Oral Session on Glomerular and Tubulo-Interstitial Diseases on June 6, 2025 [6].

Core Insights - Jade Biosciences successfully completed a reverse merger and began trading on Nasdaq under the ticker symbol JBIO, raising approximately $300 million to date, which provides a cash runway through 2027 [1][2][3] Corporate Updates - The company has transitioned to a clinical-stage entity, with its lead candidate JADE101 expected to enter first-in-human studies in the second half of 2025 [2][4] - JADE101 is an investigational anti-APRIL monoclonal antibody aimed at treating IgA nephropathy (IgAN), a chronic autoimmune kidney disease [7][8] Pipeline Developments - JADE101's first-in-human clinical trial is anticipated to begin in the second half of 2025, with interim biomarker-rich data expected in the first half of 2026 [4][6] - A second development candidate, JADE201, has been nominated from the JADE-002 antibody discovery program [5] Financial Performance - As of March 31, 2025, the company had cash and cash equivalents of $49.9 million, with a net cash used in operating activities of $18.8 million for the first quarter of 2025 [6][10] - Research and Development (R&D) expenses totaled $20.0 million for the first quarter of 2025, including $10.0 million specifically for the development of JADE101 [6][10] - The net loss for the first quarter of 2025 was $38.2 million, which includes non-cash stock-based compensation of $2.4 million [10][13]